Brivaracetam is used for managing partial-onset seizures in patients with epilepsy aged 4 years and older. It was first introduced by Ucb Inc in its drug Briviact on May 12, 2016. 5 different companies have introduced drugs containing Brivaracetam.

Brivaracetam Patents

Given below is the list of patents protecting Brivaracetam, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Briviact	US10729653	Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives	Apr 09, 2030	Ucb Inc
Briviact	US6911461	2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses	Feb 21, 2026	Ucb Inc
Briviact	US6784197	2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses	Feb 21, 2021 (Expired)	Ucb Inc
Briviact	US8492416	2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses	Feb 21, 2021 (Expired)	Ucb Inc

Add above patents to watchlist

Brivaracetam's Family Patents

Full family tree

Brivaracetam Generic API Manufacturers

Several generic applications have been filed for Brivaracetam. The first generic version for Brivaracetam was by Sunshine Lake Pharma Co Ltd and was approved on Jun 9, 2022. And the latest generic version is by Aurobindo Pharma Ltd and was approved on Jan 6, 2023.

Given below is the list of companies who have filed for Brivaracetam generic, along with the locations of their manufacturing plants worldwide.